{"id":"nefecon-ambrisentan","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Peripheral edema"},{"rate":"10-15","effect":"Headache"},{"rate":"8-12","effect":"Nasal congestion"},{"rate":"5-10","effect":"Palpitations"},{"rate":"5-8","effect":"Liver enzyme elevation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ambrisentan is an endothelin receptor antagonist (ERA) that preferentially binds to endothelin type-A (ETA) receptors. By blocking ETA receptors, it prevents endothelin-1-mediated vasoconstriction and smooth muscle proliferation in pulmonary blood vessels, thereby reducing pulmonary vascular resistance and improving hemodynamics in pulmonary arterial hypertension.","oneSentence":"Ambrisentan selectively blocks endothelin-1 receptors on vascular endothelial cells, reducing vasoconstriction and pulmonary vascular remodeling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:24:37.114Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension (PAH)"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"\"Nefecon®\",\"Ambrisentan\"","genericName":"\"Nefecon®\",\"Ambrisentan\"","companyName":"The First Hospital of Jilin University","companyId":"the-first-hospital-of-jilin-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ambrisentan selectively blocks endothelin-1 receptors on vascular endothelial cells, reducing vasoconstriction and pulmonary vascular remodeling. Used for Pulmonary arterial hypertension (PAH).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}